Last reviewed · How we verify
SGLT2 Inhibition and Left Ventricular Mass (EMPATROPHY)
Patients with type 2 diabetes mellitus are exposed to an excessive heart failure risk secondary to left ventricular hypertrophy and impaired diastolic filling, a condition not addressed by currently available treatments. The abnormality results from obesity-induced volume overload, increased blood pressure, and myocardial fat accumulation. By improving metabolism, body weight, and blood pressure, Empagliflozin addresses the root causes of type 2 diabetes-associated myocardial disease. We will assess left ventricular mass, function, and lipid content in patients with type 2 diabetes mellitus using cardiac magnetic resonance imaging and spectroscopy as well as echocardiography before and after empagliflozin or glimepiride treatment. We expect to observe improvements in left ventricular mass, function, and fat content with empagliflozin. The results of the study will help to position empagliflozin as an antidiabetic agent with the added value of protecting the heart.
Details
| Lead sponsor | Hannover Medical School |
|---|---|
| Phase | PHASE4 |
| Status | TERMINATED |
| Enrolment | 7 |
| Start date | Wed Apr 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Sep 27 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Diabetes Mellitus Type 2
Interventions
- Empagliflozin
- Glimepiride
Countries
Germany